Cannabis Study Links Two Weeks of Dispensary-Edible Use With Less Cancer Pain and Clearer Thinking

A small University of Colorado study found that cancer patients who used cannabis products purchased from dispensaries reported less pain, better sleep, and clearer thinking after two weeks. The findings, published in 2023 in Exploration of Medicine, offer an early look at how real-world cannabis products may affect cancer-related symptoms—but they do not establish that cannabis causes these improvements.

The observational study followed 25 adults with cancer who wanted to use cannabis to manage symptoms related to their disease or treatment. Rather than receiving a standardized product from researchers, participants selected their own products from medical or recreational dispensaries in Colorado. Their choices included gummies, baked goods, pills, tinctures, and other edibles with a wide range of THC and CBD concentrations.

Participants completed baseline assessments before beginning a two-week period of cannabis use. Researchers then evaluated them during an acute-use session, testing symptoms and cognitive performance before consumption and again approximately one and two hours afterward. To conduct the assessments, the research team brought a mobile laboratory—nicknamed the “cannavan”—to participants’ homes.

Short-term impairment, longer-term improvement

The immediate effects were broadly consistent with what researchers expected. Within about an hour of using cannabis, participants reported reduced pain and stronger feelings of intoxication. Some measures of cognitive performance also declined after acute use, underscoring that THC-containing products can temporarily affect attention and thinking.

After two weeks of continued, self-directed use, however, participants reported better subjective cognitive function, including feeling that they could think more clearly. Their performance also improved on the Stroop task, a test that measures aspects of attention and reaction time. The researchers proposed that reduced pain—not a direct cognitive-enhancing effect from cannabis—may help explain the improvement. Persistent pain can itself interfere with concentration and mental performance.

Participants also reported improvements in sleep quality, pain intensity, and the extent to which pain disrupted daily activities. The study did not find a significant improvement in overall quality of life during the two-week period.

What the study found about CBD and THC

The researchers also examined whether the cannabinoid makeup of participants’ products was associated with different outcomes. Greater CBD use during the two-week period was associated with steeper improvements in pain intensity and sleep quality. That result does not prove that CBD is more effective than THC, however. Participants chose their own products, used them at different doses and frequencies, and were not randomly assigned to CBD- or THC-dominant treatments.

Higher THC use during the acute testing session was associated with larger increases in reported intoxication. The study therefore illustrates both the potential benefits and tradeoffs of dispensary products: patients may experience short-term pain relief, but THC can also produce a noticeable high and temporary cognitive effects.

Why real-world cannabis products are difficult to study

Most clinical research has focused on synthetic cannabinoids, isolated compounds, or standardized products that may not resemble what consumers purchase in state-regulated markets. In this study, allowing participants to choose their own products provided a more realistic picture of how some cancer patients use cannabis outside a laboratory.

That design also introduced important limitations. The sample was very small, there was no non-cannabis control group, and the products, doses, and patterns of use varied substantially. Participants knew they were using cannabis, which means expectations may have influenced some self-reported outcomes. The study also lasted only two weeks and was not designed to determine whether cannabis affected tumor growth, cancer survival, or the course of treatment.

The study’s authors described the results as preliminary associations that should inform larger and more controlled trials. The ClinicalTrials.gov record for the research identifies it as an observational study of cannabis use in people with cancer.

For patients considering cannabis, the findings support a discussion with an oncology team rather than self-treatment. The National Cancer Institute’s review of cannabis and cannabinoids notes that evidence varies by symptom and product. The U.S. Food and Drug Administration has not approved cannabis as a cancer treatment, while the cannabinoid medicines dronabinol and nabilone are approved for certain cases of chemotherapy-related nausea and vomiting.

This Colorado study suggests that dispensary cannabis may be associated with short-term pain relief and better sleep, and that patients may feel cognitively clearer after sustained use even though they experience temporary impairment immediately after taking it. Larger randomized trials are needed to determine which products, doses, and cannabinoid combinations—if any—provide reliable benefits while minimizing risks and drug interactions.